文献速递免疫规划

巴西C群脑膜炎球菌结合疫苗的免疫原性、安全性和免疫记忆:一项II期临床试验

Immunogenicity, safety and immunological memory of a Brazilian meningococcal C conjugate vaccine on a phase II clinical trial.
PubMed 文献 · Vaccine · 2025-07-07

在360名1至9岁健康且未接种过脑膜炎球菌疫苗的儿童中开展的II期随机单盲研究,240人接种候选疫苗MenCC-Bio,120人接种对照疫苗Neisvac-C®。MenCC-Bio的血清转化率非劣效于对照疫苗,但接种后杀菌抗体几何平均滴度较低,12个月后血清逆转率较高;再接种后所有血清阴性者均转为血清阳性,提示免疫记忆良好;两种疫苗均耐受良好。

要点

  • MenCC-Bio血清转化率为226/240(94.2%;95%CI:91.0%;96.4%),Neisvac-C®为118/120(98.3%;95%CI:94.1%;99.8%),非劣效成立(差值-4.1%;95%CI:-8.5%;0.3%)。
  • 接种后杀菌抗体GMT:MenCC-Bio为230,对照疫苗为1036,试验/对照GMT比值为0.22(非劣效界值≥0.6),未达非劣效。
  • 12个月后血清逆转率MenCC-Bio为80.1%,对照疫苗为46.0%;再接种后GMT高于基础免疫后,所有血清阴性志愿者均转为血清阳性。

核心结论

  • MenCC-Bio疫苗与Neisvac-C®同样安全,但免疫原性较低。
  • 尽管如此,其高血清转化率和免疫记忆的诱导表明该疫苗在免疫规划中有用。

研究设计与样本

  • II期随机单盲研究,纳入360名1至9岁健康且未接种过脑膜炎球菌疫苗的儿童。
  • 240名接种候选疫苗MenCC-Bio,120名接种对照疫苗Neisvac-C®。
  • 候选疫苗由Bio-Manguinhos/Fiocruz研发,每剂含C群脑膜炎球菌多糖10 μg(菌株2135)与破伤风类毒素(10-30 μg)结合,以及氢氧化铝(0.35 mg Al+3)。

主要发现

  • 血清转化率:MenCC-Bio为226/240(94.2%;95%CI:91.0%;96.4%),Neisvac-C®为118/120(98.3%;95%CI:94.1%;99.8%);MenCC-Bio被判定为非劣效(血清转化率差值-4.1%;95%CI:-8.5%;0.3%)。
  • 接种后杀菌抗体GMT:MenCC-Bio为230,对照疫苗为1036;试验/对照接种后GMT比值为0.22(非劣效界值≥0.6)。
  • 5岁以下儿童的免疫原性差异更大。
  • 在12个月后重新评估的儿童亚组中,MenCC-Bio的血清逆转率为80.1%,对照疫苗为46.0%。
  • 再接种后GMT高于基础免疫后,所有血清阴性志愿者均转为血清阳性,表明免疫记忆强。

关键数值与推荐

  • 血清转化定义为杀菌抗体滴度转至≥1:8或血清杀菌活性滴度4倍升高。
  • 非劣效界值:GMT比值≥0.6。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Meningococcal disease (MD) is a public health burden. In many countries, including Brazil, serogroup C (MenC) is the main cause of MD, emphasizing the importance of continuous improvement of MenC conjugate vaccines. METHODS: Phase II randomized, single-blinded study, with 360 healthy and meningococcal vaccine-naive children from 1 to 9 years of age: 240 received the candidate MenCC-Bio vaccine and 120 received the reference vaccine Neisvac-C®. The test vaccine was developed by Bio-Manguinhos∕Fiocruz and contained per dose: meningococcal C polysaccharide 10 μg (strain 2135) conjugated to tetanus toxoid (10-30 μg), and aluminum hydroxide (0.35 mg Al+3). Seroconversion (i.e., conversion to ≥1:8 or a 4-fold increase in serum bactericidal activity titers) and geometric mean titers (GMT) were evaluated. Adverse events were recorded for 30 days following vaccination. Duration of seroprotection was assessed 12 months after primary vaccination, and a booster dose was administered in children who had seroconverted initially. RESULTS: Seroconversion rates were 226/240 (94.2 %; 95 % CI: 91.0 %; 96.4 %) for MenCC-Bio and 118/120 (98.3 %; 95 % CI: 94.1 %; 99.8 %) for Neisvac-C®. MenCC-Bio was considered non-inferior (difference in seroconversion -4.1 %; 95 % CI: -8.5 %; 0.3 %). However, post-vaccination bactericidal GMT was inferior (MenCC-Bio = 230; Reference vaccine = 1036), and test/reference GMT post-vaccination ratio was 0.22 (non-inferiority cutoff ≥0.6). Differences in immunogenicity were higher for children <5 years old. In the subset of children reassessed after 12 months, seroreversion for MenCC-Bio was 80.1 % and 46.0 % for the reference vaccine. Post-revaccination GMT was higher than after primary vaccination, and all seronegative volunteers became seropositive, indicating strong immunological memory. Both vaccines were well tolerated, and adverse events were mild or moderate. CONCLUSION: MenCC-Bio vaccine was equally safe but had lower immunogenicity compared to Neisvac-C®. Nevertheless, the high seroconversion rate and induction of immunological memory indicates its usefulness in Immunization Programs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Martins RM, Marques CMC, Noronha TG, et al. Immunogenicity, safety and immunological memory of a Brazilian meningococcal C conjugate vaccine on a phase II clinical trial. Vaccine. 2025. PMID: 40627869. doi:10.1016/j.vaccine.2025.127419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。